| +0.66 / +4.46%|
The 8 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 23.00, with a high estimate of 30.00 and a low estimate of 20.00. The median estimate represents a +48.67% increase from the last price of 15.47.
The current consensus among 8 polled investment analysts is to Buy stock in Keryx Biopharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.